In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...

Years of translational research have successfully improved treatment outcomes for common dermatological conditions such as ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Researchers found that while sweat biomarkers remain stable, plasma biomarkers show significant inflammatory changes after a ...

Scientists explore how the immune and nervous systems constantly communicate, influencing brain diseases, behavior, and ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

"Eli Lilly reports positive data from trial of Omvoh for Crohn’s disease" was originally created and published by Clinical ...

Harvard researchers have found that M. morganii may contribute to depression by producing an inflammatory molecule.

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion and impressive revenue growth of 32% in the last twelve months, has ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an osteoarthritis treatment in human trials may have potential for treating RA.

Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical ... immune tolerance for the remission of active lupus. Diminished interleukin ...